Sign in or Register   Sign in or Register
  |  

Mouse Anti-DPYD Recombinant Antibody (CBYCD-397) (CBMAB-D1641-YC)

Provided herein is a Mouse monoclonal antibody, which binds to Dihydropyrimidine Dehydrogenase (DPYD). The antibody can be used for immunoassay techniques, such as WB, ICC, IHC-P, IHC-Fr, ELISA.
See all DPYD antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYCD-397
Antibody Isotype
IgG
Application
WB, ICC, IHC-P, IHC-Fr, ELISA

Basic Information

Immunogen
Dihydropyrimidine Dehydrogenase
Specificity
Human
Antibody Isotype
IgG
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Dihydropyrimidine Dehydrogenase
Introduction
DPYD is a pyrimidine catabolic enzyme and the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Mutations in this gene result in dihydropyrimidine dehydrogenase deficiency, an error in pyrimidine metabolism associated with thymine-uraciluria and an increased risk of toxicity in cancer patients receiving 5-fluorouracil chemotherapy.
Entrez Gene ID
1806
UniProt ID
Q12882
Alternative Names
Dihydropyrimidine Dehydrogenase; Dihydrothymine Dehydrogenase; Dihydrouracil Dehydrogenase; EC 1.3.1.2; DHPDHASE; DPD; Dihydropyrimidine Dehydrogenase [NADP(+)]; DHP;
Function
Involved in pyrimidine base degradation. Catalyzes the reduction of uracil and thymine. Also involved the degradation of the chemotherapeutic drug 5-fluorouracil.
Biological Process
Beta-alanine biosynthetic process Source: UniProtKB-UniPathway
Purine nucleobase catabolic process Source: UniProtKB
Pyrimidine nucleobase catabolic process Source: UniProtKB
Thymidine catabolic process Source: UniProtKB
Thymine catabolic process Source: UniProtKB
Uracil catabolic process Source: UniProtKB
Cellular Location
Cytoplasm
Involvement in disease
Dihydropyrimidine dehydrogenase deficiency (DPYDD):
A metabolic disorder with large phenotypic variability, ranging from no symptoms to a convulsive disorder with motor and mental retardation. It is characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil.

Hamzic, S., Schärer, D., Offer, S. M., Meulendijks, D., Nakas, C., Diasio, R. B., ... & Largiadèr, C. R. (2021). Haplotype structure defines effects of common DPYD variants c. 85T> C (rs1801265) and c. 496A> G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5‐fluorouracil toxicity. British journal of clinical pharmacology, 87(8), 3234-3243.

Wigle, T. J., Povitz, B. L., Medwid, S., Teft, W. A., Legan, R. M., Lenehan, J., ... & Kim, R. B. (2021). Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clinical and translational science, 14(4), 1338-1348.

Naushad, S. M., Hussain, T., Alrokayan, S. A., & Kutala, V. K. (2021). Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population. The Journal of Gene Medicine, 23(1), e3289.

Wörmann, B., Bokemeyer, C., Burmeister, T., Köhne, C. H., Schwab, M., Arnold, D., ... & Hofheinz, R. D. (2020). Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper. Oncology research and treatment, 43(11), 628-636.

Coenen, M. J., Paulussen, A. D., Breuer, M., Lindhout, M., Tserpelis, D. C., Steyls, A., ... & van den Bosch, B. J. (2019). Evolution of dihydropyrimidine dehydrogenase diagnostic testing in a single center during an 8-year period of time. Current Therapeutic Research, 90, 1-7.

Murphy, C., Byrne, S., Ahmed, G., Kenny, A., Gallagher, J., Harvey, H., ... & Bird, B. (2018). Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: A single-institution experience. Dose-Response, 16(4), 1559325818803042.

Shrestha, S., Zhang, C., Jerde, C. R., Nie, Q., Li, H., Offer, S. M., & Diasio, R. B. (2018). Gene‐specific variant classifier (DPYD‐varifier) to identify deleterious alleles of dihydropyrimidine dehydrogenase. Clinical Pharmacology & Therapeutics, 104(4), 709-718.

Henricks, L. M., Siemerink, E. J., Rosing, H., Meijer, J., Goorden, S. M., Polstra, A. M., ... & van Kuilenburg, A. B. (2018). Capecitabine‐based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency. International Journal of Cancer, 142(2), 424-430.

Gokare, P., Finnberg, N. K., Abbosh, P. H., Dai, J., Murphy, M. E., & El-Deiry, W. S. (2017). P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting. Scientific reports, 7(1), 1-12.

Del Re, M., Restante, G., Di Paolo, A., Crucitta, S., Rofi, E., & Danesi, R. (2017). Pharmacogenetics and metabolism from science to implementation in clinical practice: the example of dihydropyrimidine dehydrogenase. Current Pharmaceutical Design, 23(14), 2028-2034.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-DPYD Recombinant Antibody (CBYCD-397)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare